The Virtual Biotech is introduced, an organization of artificial intelligence agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development, which demonstrates its utility at three drug-development decision points.
Abstract
Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development. We demonstrate its utility at three drug-development decision points. First, over 37,000 agents annotated outcomes from 55,984 trials and found that drugs targeting cell-type-specific genes were 48% more likely to reach market with 32% fewer adverse events. Second, it integrated multimodal evidence to propose a therapeutic strategy in lung cancer. Third, it analyzed a terminated ulcerative colitis trial and inferred potential mechanisms of failure. These results demonstrate that human-guided multi-agent systems can conduct transparent, multiscale analyses to inform therapeutic-development decisions.
A paradigm shift toward autonomous scientific agents capable of causal reasoning and end-to-end experimental guidance is highlighted, and persistent challenges are discussed, including data bias, limited interpretability, and in silico-to-wet lab translation.
It is argued that clinical value will depend on closed-loop workflows in which multimodal predictions are experimentally validated, externally tested, and longitudinally updated to guide the next therapeutic decision.
K. Papavassiliou, A. Sofianidi, Angeliki Margoni et al.· International Journal of Mol...· 0 citations
An OpenAI-based framework was developed to systemically analyze terminated trials on ClinicalTrials.gov and may provide a new direction to apply AI technologies for drug development, and inspire future investigations of clinical reports and public information from the perspective of delivery technology applications.
TrialAtlas is introduced, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk.
Jia-Cheng Lin, Zifeng Wang, Zheng Chen et al.· 0 citations
The resources and modeling advances supporting AI virtual cells' value for mechanism-of-action analysis, efficacy, safety, resistance, and combination studies are reviewed, and evidence requirements for pharmacological use are defined.
Shi-Hang Wang, Yang Zhang, Dong Wang et al.· TIPS - Trends in Pharmacolog...· 0 citations
This evidence-based literature review critically examines the evolution and application of computational technologies across the pharmaceutical pipeline, ranging from early expert systems like DENDRAL, computer-aided drug design (CADD), and quantitative structure-activity relationship (QSAR) modeling to AlphaFold 3 bio...
Leonardo Mairene Muniz· Brazilian Journal of Health...· 0 citations